Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer

Next Previous
Trial Profile

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 25 Apr 2018 Planned End Date changed from 25 Feb 2023 to 1 Dec 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top